Certain Restricted Stock Units of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.
May 11, 2024
Share
Certain Restricted Stock Units of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024. These Restricted Stock Units will be under lockup for 61 days starting from 11-MAR-2024 to 11-MAY-2024.
Details:
The company, it's executive officers and directors and certain of stockholders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 60 days after the date of this prospectus supplements
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.